Devazepide
Chemical compound
- none
- N-(1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide
- 103420-77-5 Y
- 443375
- 878
- 391607 N
- JE6P7QY7NH
- D02693 Y
- ChEMBL9506 N
- DTXSID2046092
- Interactive image
- O=C(c2cc1ccccc1[nH]2)N[C@H]3/N=C(\c4ccccc4N(C3=O)C)c5ccccc5
InChI
- InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1 N
- Key:NFHRQQKPEBFUJK-HSZRJFAPSA-N N
Devazepide[1] (L-364,718, MK-329) is benzodiazepine drug, but with quite different actions from most benzodiazepines, lacking affinity for GABAA receptors and instead acting as an CCKA receptor antagonist.[2] It increases appetite and accelerates gastric emptying,[3][4] and has been suggested as a potential treatment for a variety of gastrointestinal problems including dyspepsia, gastroparesis and gastric reflux.[5] It is also widely used in scientific research into the CCKA receptor.[6][7]
Synthesis
Devazepide is synthesised in a similar manner to other benzodiazepines.[8][9]
See also
- Benzodiazepine
- Cholecystokinin antagonist
References
- ^ US 4820834, Evans, Ben E.; Freidinger, Roger M. & Bock, Mark G., "Benzodiazepine analogs", published 1989-04-11, assigned to Merck & Co. Inc.
- ^ Hill DR, Woodruff GN (September 1990). "Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260". Brain Research. 526 (2): 276–83. doi:10.1016/0006-8993(90)91232-6. PMID 2257485. S2CID 23851131.
- ^ Cooper SJ, Dourish CT (December 1990). "Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding". Physiology & Behavior. 48 (6): 849–57. doi:10.1016/0031-9384(90)90239-z. PMID 1982361. S2CID 24850080.
- ^ Cooper SJ, Dourish CT, Clifton PG (January 1992). "CCK antagonists and CCK-monoamine interactions in the control of satiety". The American Journal of Clinical Nutrition. 55 (1 Suppl): 291S–295S. doi:10.1093/ajcn/55.1.291s. PMID 1728842.
- ^ Scarpignato C, Varga G, Corradi C (1993). "Effect of CCK and its antagonists on gastric emptying". Journal of Physiology, Paris. 87 (5): 291–300. doi:10.1016/0928-4257(93)90035-r. PMID 8298606. S2CID 23725376.
- ^ Weller A (July 2006). "The ontogeny of postingestive inhibitory stimuli: examining the role of CCK". Developmental Psychobiology. 48 (5): 368–79. doi:10.1002/dev.20148. PMID 16770766.
- ^ Savastano DM, Covasa M (October 2007). "Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors". Physiology & Behavior. 92 (3): 434–42. doi:10.1016/j.physbeh.2007.04.017. PMID 17531277. S2CID 5566756.
- ^ Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, et al. (December 1988). "Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists". Journal of Medicinal Chemistry. 31 (12): 2235–46. doi:10.1021/jm00120a002. PMID 2848124.
- ^ EP 1492540, Jackson, Karen, "The use of devazepide as analgesic agent", published 2005-01-05, assigned to ML Laboratories plc
- v
- t
- e
- 2-Oxoquazepam
- 3-Hydroxyphenazepam
- Bromazepam
- BMS-906024*
- Camazepam
- Carburazepam
- Chlordiazepoxide
- Cinazepam
- Cinolazepam
- Clonazepam
- Cloniprazepam
- Clorazepate
- Cyprazepam
- Delorazepam
- Demoxepam
- Desmethylflunitrazepam
- Devazepide*
- Diazepam
- Diclazepam
- Difludiazepam
- Doxefazepam
- Elfazepam
- Ethyl carfluzepate
- Ethyl dirazepate
- Ethyl loflazepate
- Flubromazepam
- Fletazepam
- Fludiazepam
- Flunitrazepam
- Flurazepam
- Flutemazepam
- Flutoprazepam
- Fosazepam
- Gidazepam
- Halazepam
- Iclazepam
- Irazepine*
- Kenazepine
- Ketazolam
- Lorazepam
- Lormetazepam
- Lufuradom*
- Meclonazepam
- Medazepam
- Menitrazepam
- Metaclazepam
- Motrazepam
- N-Desalkylflurazepam
- Nifoxipam
- Nimetazepam
- Nitemazepam
- Nitrazepam
- Nitrazepate
- Nordazepam
- Nortetrazepam
- Oxazepam
- Phenazepam
- Pinazepam
- Pivoxazepam
- Prazepam
- Proflazepam
- Quazepam
- QH-II-66
- Reclazepam
- RO4491533*
- Ro05-4082
- Ro5-4864*
- Ro07-5220
- Ro07-9749
- Ro20-8065
- Ro20-8552
- SH-I-048A
- Sulazepam
- Temazepam
- Tetrazepam
- Tifluadom*
- Timelotem*
- Tolufazepam
- Triflunordazepam
- Tuclazepam
- Uldazepam
* atypical activity profile (not GABAA receptor ligands)